We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Zenobia Announces Sale of Commercial Fragment Library for Crystallographic, NMR and SPR Screening
Product News

Zenobia Announces Sale of Commercial Fragment Library for Crystallographic, NMR and SPR Screening

Zenobia Announces Sale of Commercial Fragment Library for Crystallographic, NMR and SPR Screening
Product News

Zenobia Announces Sale of Commercial Fragment Library for Crystallographic, NMR and SPR Screening


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Zenobia Announces Sale of Commercial Fragment Library for Crystallographic, NMR and SPR Screening"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Zenobia Therapeutics, Inc. has announced that they are adding a 352 compound fragment library to their product offerings. The library is ready for screening by X-ray, NMR, and SPR methods, contains soluble, verified protein binders, is shape and functionally diverse, and has an average molecular weight of 155 Da.

According to Company, the compounds are pre-plated and will initially cost approximately $11/compound. The library was constructed by Zenobia's team of seasoned FBLD professionals. Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia, reported the first fragment-based crystallographic screening method in 2000.

"Over the past decade, FBLD has become a successful drug discovery method that has produced many NCEs and clinical candidates. We want FBLD to continue to positively impact drug discovery and are now providing a solid, simple starting point for fragment-based screening campaigns," said Dr. Nienaber.

"A great deal of the chemical space of drug-like molecules can be covered by a well chosen set of small fragment compounds. This efficient library design will provide researchers with a lot of information on target site binding within a small number of experiments," said John Badger, Ph.D., Director of Structural Biology. The library has been examined by Dr. Ruo Steensma, Ph.D., Director of Chemistry for Zenobia Therapeutics. Dr. Steensma took forward two programs to IND using FBLD during her tenure as Director of Medicinal Chemistry at SGX Pharmaceuticals.
Advertisement